Sun Ying, Liu Peiru, Lv Dongyang, Yang Defu, Qiao Shiyu, Liu Jing, Yan Ying, Wang Wenping
Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang, 110031, China.
Department of Radiation Oncology, General Hospital of Northern Theater Command, Shenyang, 110016, China.
Discov Oncol. 2025 Jun 15;16(1):1110. doi: 10.1007/s12672-025-02852-1.
A comprehensive pan-cancer analysis of HES6 was conducted to investigate the differential expression patterns, clinical implications, and prognostic significance of HES6 across multiple cancer types, while also aiming to elucidate the underlying biological mechanisms of HES6 in oncogenesis. HES6 plays a pivotal regulatory role in the progression of numerous malignant tumors, profoundly influencing the survival duration of patients with solid tumors and demonstrating a strong correlation with the immune microenvironment. Notably, HES6 is generally overexpressed in a wide range of cancer types, exhibiting significant divergence from its expression levels in normal tissues. Furthermore, HES6 has been found to serve as a predictive indicator of survival outcomes in patients with various solid tumors. The gene expression profile of HES6 and its associated genes is predominantly enriched in CD8 + T cells and macrophages. Additionally, HES6 and its cognate genes are significantly enriched within critical signaling cascades, including the "Epithelial-Mesenchymal Transition Pathway," "NOTCH Signaling," and the "Wnt signaling activation," among others. HES6 may exert its influence on cellular function and oncogenic behaviors through interactions with HES1 and other proteins. It also demonstrates a robust association with a multitude of inflammation-related genes, immunomodulatory genes, and receptor genes across diverse cancer types. Based on these findings, it is hypothesized that HES6 may emerge as a potential clinical biomarker for solid tumors, particularly gliomas.
对HES6进行了全面的泛癌分析，以研究HES6在多种癌症类型中的差异表达模式、临床意义和预后意义，同时旨在阐明HES6在肿瘤发生中的潜在生物学机制。HES6在众多恶性肿瘤的进展中发挥着关键的调节作用，深刻影响实体瘤患者的生存时间，并与免疫微环境表现出强烈的相关性。值得注意的是，HES6在广泛的癌症类型中通常过表达，与其在正常组织中的表达水平存在显著差异。此外，已发现HES6可作为各种实体瘤患者生存结果的预测指标。HES6及其相关基因的基因表达谱主要富集于CD8 + T细胞和巨噬细胞中。此外，HES6及其同源基因在关键信号级联反应中显著富集，包括“上皮-间质转化途径”、“NOTCH信号”和“Wnt信号激活”等。HES6可能通过与HES1和其他蛋白质相互作用来影响细胞功能和致癌行为。它还在不同癌症类型中与多种炎症相关基因、免疫调节基因和受体基因表现出强烈的关联。基于这些发现，推测HES6可能成为实体瘤，特别是神经胶质瘤的潜在临床生物标志物。
